Eric Jonasch, M.D.

MD Anderson Cancer Center

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dr. Eric Jonasch, a seasoned professional in the field of Genitourinary Medical Oncology, holds the position of Professor in the Department of Genitourinary Medical Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. With a career marked by academic excellence and leadership, Dr. Jonasch has been a driving force in advancing crucial research initiatives for patients with kidney cancer and von Hippel-Lindau disease.

 

Educational Background:

Dr. Jonasch is currently a tenured Professor at The University of Texas MD Anderson Cancer Center.

 

Education & Training:

Degree-Granting Education
1988: McGill University, Montreal, CAN, BSc, Biochemistry

Postgraduate Training
1997–1999: Research Fellowship, Beth Israel Deaconess Medical Center, Boston, MA
1995–1997: Research Fellowship, Hematology/Oncology, New England Medical Center, Boston, MA
1995–1997: Clinical Fellowship, New England Medical Center, Boston, MA
1992–1995: Clinical Residency, Internal Medicine, Royal Victoria Hospital, Montreal
1988–1992: MDCM, McGill Medical School, Montreal

 

Board Certifications

2000: Medical Oncology American Board of Internal Medicine
2000: Medicine, Royal College of Physicians & Surgeons of Canada
2000: Oncology, Royal College of Physicians & Surgeons of Canada
1999: Hematology, American Board of Internal Medicine
1995: Internal Medicine, American Board of Internal Medicine

 

Honors & Awards

2015: Irwin H. Krakoff Award for Excellence in Clinical Research, MD Anderson Cancer Center
2009: Young Texans Against Cancer Research Award
2008: Renal Cell Carcinoma Translational Research, American University-Beirut
1997: Molecular Biology Research Seminar for Young Investigators, American Association for Cancer Research

Professional Appointments and Responsibilities:

Dr. Jonasch is the Director of the von Hippel Lindau Center at MD Anderson Cancer Center.

 

Academic Contributions:

As a member of the Graduate School of Biomedical Science at The University of Texas Health Science Center since 2004, Dr. Jonasch has played a vital role in bridging the gap between academia and medical research. His academic contributions have not only shaped the educational landscape but have also influenced the trajectory of biomedical science, contributing to the collective knowledge base. Dr. Jonasch has published more than 280 academic papers and was the lead investigator of a study that led to the first approved drug for patients with von Hippel-Lindau disease.

 

Consultantships:

Dr. Jonasch’s involvement in medical advisory boards highlights his dedication to patient advocacy and support. As a Medical Advisory Board Member for the Von Hippel Lindau (VHL) Family Alliance in Boston, MA, since 2007, and a member of the International Kidney Cancer Coalition since 2016, he actively contributes to shaping initiatives that impact patient care, emphasizing a holistic approach to cancer management.

 

Leadership and Impact:

Dr. Jonasch currently leads the Department of Defense-funded Kidney Cancer Research Consortium and the von Hippel-Lindau Research Consortium. Dr. Jonasch is also the Vice Chair of the National Comprehensive Cancer Network Kidney Cancer Guidelines.

“By fostering collaboration amongst centers of excellence, we will accelerate the development of cutting edge therapies and diagnostic techniques for patients with kidney cancer.”

Publications

Jonasch and Srinivasan NEJM PMID: 34818478

 

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease

Choueri and Jonasch  Nat Med PMID PMID: 33888901

 

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Naomi Haas, MD | Kidney Cancer Research Consortium

Naomi Haas

UPenn

Daniel George, MD | Kidney Cancer Research Consortium

Daniel George

Duke University

Hans Hammers

UT Southwestern

David McDermott, MD | Kidney Cancer Research Consortium

David McDermott

Beth Israel

Brian Rini, MD | Kidney Cancer Research Consortium

Brian Rini

Vanderbilt University

Ulka Vaishampayan, MD | Kidney Cancer Research Consortium

Ulka Vaishampayan

University of Michigan